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ABSTRACT
Objective: To validate previously discovered miRNAs (miR-31-5p and miR-149-
5p) as prognostic factors for UTUC in an independent cohort of UTUC patients.
Patients and Methods: Multicenter, international and retrospective study of formalin-
fixed paraffin-embedded tissue samples from 103 UTUC patients (45 progressing and 58 
non-progressing) who underwent radical nephroureterectomy. Total RNA was isolated and 
reverse transcribed. The expression of target miRNAs (miR-31-5p and miR-149-5p) and 
the endogenous control miR-218-5p was evaluated in all samples by reverse transcription 
quantitative PCR. Normalized miRNA expression values were evaluated by multivariate 
forward stepwise Cox regression analysis. Kaplan Meier curves were used to discriminate 
between two groups of patients with a different probability of tumour progression.
Results: The mean age (range) of the series was 67 (33-94) years. Overall, 45 
patients (43.7%) developed tumour progression and 32 patients (31.2%) died, 20 of 
these (62.5%) due to their UTUC, after a median follow-up of 36 months. The mean 
time for tumour progression and cancer-specific survival were 15 and 20 months, 
respectively. Five year tumour progression free survival and cancer-specific survival 
were 58% for ≤ pT2, 36% for pT3 and 0% for pT4 and 67.8% for ≤ pT2, 50.6% for 
pT3 and 0% for pT4, respectively. In the multivariate analysis, expression of miR-31-
5p was found to be an independent prognostic factor of tumour progression (HR 1.1; 
95% CI 1.039-1.273; p=0.02). Kaplan Meier curve shows that miR-31-5p expression 
values are able to discriminate between two groups of UTUC patients with a different 
probability of tumour progression (p=0.007).
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Conclusions: We have been able to validate our previous results in an independent 
multicentre international cohort of UTUC patients, suggesting that miRNA-31-
5p could be a useful prognostic marker of UTUC progression. The application 
of miRNA expression values to clinical practice could refine the currently used 
clinicopathological-based approach for predicting UTUC patients’ outcome.
INTRODUCTION
Upper tract urothelial carcinomas (UTUCs) are 
uncommon and account for only a small number (5-10%) of 
urothelial carcinomas. The majority of UTUCs are invasive 
at diagnosis compared to bladder tumours having only up to 
a quarter invasive at presentation[1, 2]. Due to the aggressive 
nature of UTUC, radical nephroureterectomy (RNU) remains 
the “gold standard” treatment for localized tumours [3].
Established prognostic factors associated with 
tumour progression and survival are pathological stage 
and tumour grade. However, they are insufficient to 
predict the individual outcome for UTUC patients 
[4, 5]. A greater understanding of the biological 
behaviour of tumours would allow individualized 
medicine, in an attempt to decrease morbidity and 
importantly improve survival. microRNAs (miRNAs) 
are a family of short (average of 22nt long), naturally 
occurring, small antisense non-coding RNAs, that have 
emerged as important post-transcriptional regulators 
of gene expression [6]. They have wide distribution as 
endogenous controllers of gene expression by binding 
to the 3’-untranslated region of specific miRNAs [7, 
8]. As miRNAs may regulate a significant portion of 
the transcriptome and proteome, considerable attention 
has focused on miRNAs as mediators or biomarkers 
of disease [9, 10]. miRNAs are critical to cancer 
pathogenesis, as they can act as oncogenes or tumor 
suppressor genes. They may also have potential value as 
prognostic or diagnostic biomarkers in the clinical setting 
[11]. Many cancers have had dysregulation of miRNAs 
documented [12-14], including urothelial tumours such 
as bladder cancer [15] and UTUC [16, 17].
We have previously examined the miRNA 
expression pattern of UTUC tissue samples from 
progressing and non-progressing patients in order to 
identify putative miRNAs that may be used as prognostic 
markers in UTUC. miRNA-31-5p and miRNA-149-
5p have been identified as prognostic factors of tumour 
progression and cancer specific survival [17]. In the 
present study, we aim to retrospectively validate miRNA-
31-5p and miRNA-149-5p as prognostic markers of 
UTUC in a multicenter cohort of UTUC patients.
RESULTS
Patient characteristics
The final cohort consisted of 103 patients. Median 
age (range) of the cohort was 67 (33-94) years. Gender 
balance favored men 83:20. The median (range) follow-
up oin this series was 36 (6-384) months. The patients’ 
histopathological characteristics are outlined in Table 1.
Overall 45 patients (43.7%) recorded progression 
of their tumours at a median follow-up of 36 months. 
Tumour progression occurred at a median of 15 (2-168) 
months. By pathological stage, one and five year tumour 
progression free survival were 80% for ≤ pT2, 76% for 
pT3 and 45% for pT4 and 58% for ≤ pT2, 36% for pT3 
and 0% for pT4, respectively (p<0.05) (Figure 1).
During follow-up, 32 patients (31.2%) died, 20 of them 
(62.5%) due to their UTUC. One was pTa (5%), two were 
pT1 (10%), three pT2 (15%), eight pT3 (40%) and six pT4 
(30%). Disease other than UTUC accounted for mortality in 
twelve patients. The median (range) time to cancer-specific 
death was 20 (9-85) months. Based on pathological stage, the 
one and five year cancer-specific survival were 96.5% for ≤ 
pT2, 65.7% for pT3 and 40% for pT4 and 67.8% for ≤ pT2, 
50.6% for pT3 and 0% for pT4, respectively (p<0.05).
Correlations between clinical features and 
miRNA expression
We found that histological grade correlated with 
pathological stage (R=0.53, p=0.001). In addition, 
miRNA-31-5p correlated with histological grade (R=0.21, 
p=0.03) and pathological stage (R=0.29, p=0.002). Non-
significant correlations were found between miRNA-149-
5p with histological grade (p=0.589) and pathological 
stage (p=0.495).
Association of miRNA expression with 
progression and survival
The expression pattern of miR-31-5p and miR-149-5p 
are provided in Supplementary Figure 1 of supplementary 
material. To verify whether these two selected miRNAs (miR-
31-5p and miR-149-5p) were independent prognostic factors 
of patients’ progression and survival, the miRNAs expressions 
were analyzed using a Cox regression model. Univariate 
analysis including miRNA-31-5p and miRNA-149-5p showed 
that the expression of miRNA-31-5p was an independent 
prognostic factor of tumour progression (HR=1.107; 95% 
CI 1.008-1.217, p=0.033 and HR=0.998; 95% CI 0.831-
1.199, p=0.985, respectively). Multivariate regression 
analysis demonstrated that expression of miRNA-31-5p 
was an independent prognostic factor of tumour progression 
(HR=1.1; 95% CI 1.039-1.279, p=0.02). Contrarily, the two 
miRNAs were not associated with cancer-specific survival.
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miRNA-31-5p expression values are able to 
discriminate between two groups of UTUC patients with 
a different probability of tumour progression (p=0.007) 
using Kaplan Meier curves. UTUC samples with miRNA-
31-5p expression values (ΔCt) greater than the cutoff value 
(-2.27) have a greater risk of tumour progression (high-
risk group) and samples with miRNA-31-5p expression 
values lower/equal than the cutoff value have low risk 
tumour progression (low risk group) (Figure 1).
Target prediction and functional enrichment of 
miR-31-5p
The DIANA-miRPath miRNA analysis, with 
miRNA-31-5p, shows several statistically significant 
predicted Kyoto Encyclopedia of Genes and Genomes 
(KEGG) terms related with the adherens junction, TNF 
signalling pathway, cGMP-PKG signalling pathway 
among others (Supplementary Table 1 of supplementary 
material).
DISCUSSION
The prognosis of UTUC remains unpredictable 
in many instances. Approximately one third of UTUC 
patients die from their tumour after five years of follow-up 
and the commonly utilised prognostic factors are unable 
to accurately predict individual tumour behaviour [18]. 
Therefore predicting disease progression in a specific 
patient remains a challenge. Several molecular prognostic 
biomarkers have been previously investigated in UTUC 
patients [19-27], but have not transitioned to becoming 
clinically valuable tools as yet.
Identification of new prognostic tools is of great 
interest in UTUC to adapt treatments according to 
the molecular risk of a particular tumour. If we could 
identify a patient with a high risk of progression (clinical, 
molecular or both), it would be possible to increase 
surveillance intervals and/or consider additional treatments 
such as chemotherapy. Experimental work has shown 
that miRNAs are dysregulated in most cancer types and 
have demonstrated significant diagnostic and prognostic 
value in different malignancies [28-31]. In the case of 
UTUC, there are only a few studies evaluating miRNAs as 
diagnostic biomarkers. Kriebel et al. reported that miRNA 
expression is altered in UTUC and showed that circulating 
miRNA-141 may be useful as diagnostic biomarker [32]. 
Tao et al. identified a ten-serum miRNA-based expression 
profile that was useful in discriminating between UTUC 
cases and controls [16].
















Patients 36 22 5 40 103 (100)
Gender (male/
female)
31/5 18/4 4/1 30/10 —
Median age 64 67 74 73 —
Histological 
Grade
I 1 8 2 2 13 (12.6)
II 9 10 0 18 37 (35.9)
III 26 4 3 20 53 (51.5)
Pathological 
Stage
pTa 8 4 1 8 21 (20.4)
pT1 4 2 1 8 15 (14.6)
pT2 5 8 1 7 21 (20.4)
pT3 11 8 2 12 33 (32)
pT4 6 0 0 5 11 (10.7)
pTis 2 0 0 0 2 (1.9)
N+ 5 7 0 8 20 (19.4)
M+ 2 3 0 1 6 (5.8)
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However, as far as we could ascertain, our group 
was the first to explore the potential prognostic value of 
miRNA expression profiles in UTUC patients [17]. Using 
a global miRNA profiling of UTUC samples, we identified 
26 miRNAs differentially expressed within tissue samples 
from patients with progressive and non-progressive 
UTUC. After validation of such miRNAs using an 
independent multicenter cohort, we were able to identify 
miRNA-31-5p and miRNA-149-5p as independent 
predictors of tumour progression. Here, we report the 
validation of these two previously discovered prognostic 
miRNAs in an independent international multicenter 
series of UTUC patients. As demonstrated, miRNA-
31-5p expression predicts tumour progression in this 
independent cohort. Hence miRNA-31-5p discriminated 
between two groups with a highly significant differential 
probability of tumour progression. Thus, miRNA-31-5p 
provides a biomarker to identify a sub-group of patients 
with a poorer prognosis and may help redefine the current 
clinicopathological approach making it a valuable clinical 
tool.
In addition, we found a statistical correlation 
between miR-31-5p with the most established prognostic 
factors in UTUC, histological grade and pathological 
stage.
miRNA-31-5p has been previously reported to be 
upregulated in colon, lung and cervical cancer [33-35]. On 
the other hand, miRNA-31-5p was found down-regulated 
in bladder, prostate, gastric, breast and serous ovarian 
cancer [36, 37]. These data suggested that miRNA-31-5p 
can behave either as tumour suppressor or as an oncogenic 
miRNA, which may be dependent on the cancer type. In 
concordance with our previous results, we found a down-
regulation of miRNA-31-5p in progressive UTUC patients 
[17]. Interestingly, Wang et al. revealed that miRNA-
31-5p was down-regulated in bladder cancer patients 
with an unfavourable outcome [38]. The miRNA-31-5p 
gene is located on 9p21.3. DNA lost at 9p21 has been 
frequently observed in bladder and UTUC patients [39, 
40]. Across differing cancer types, genetic variants of the 
9p21 region have been associated with the development of 
multiple cancers which suggests this region’s importance 
[41]. Therefore, downregulation of miRNA-31-5p is in 
accordance with the loss of this chromosomal region in 
urothelial cancers. Moreover, in support of our study, it has 
been reported that suppression of miRNA-31-5p enhances 
Figure 1: Kaplan Meier curve of tumor progression according to miRNA-31-5p expression values.
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chemotherapy effectiveness (5-fluoracil) at earlier stages, 
and additionally interferes with cell migration and 
invasion of colon cancer cells [37].
Furthermore, analysis of KEGG pathways 
corroborates that miRNA-31-5p is biologically 
meaningful. Several possible signalling pathways, 
such as the adherens junction, TNF signalling pathway, 
cGMP-PKG signalling pathway were predicted to be 
modified by miRNA-31-5p. Among others, the adherens 
junction contributes to cells physical linking and 
regulating of cell–cell contacts both critical for tissue 
and organ morphogenesis and remodeling. TNF is a pro-
inflammatory cytokine that plays a crucial role across a 
range of cellular activities from proliferative through to 
apoptotic events. TNF has also been identified in cell 
dysregulation that leads to disease making it a target of 
interest for molecular study. It appears that many signal 
pathways are involved which lead to the observed TNF-
mediated biological responses [42]. cGMP-PKG is 
implicated in the regulation of cell division and synthesis.
One of the potential strengths of this study is the 
methodology whereby we were able to use archival 
FFPE samples to obtain miRNA expression patterns. 
This has implications for clinical practice due to the 
ability to quickly translate results from “bench-to-
bedside”. Moreover, this study represents a multicenter 
international cohort with long-term follow-up, making 
the data more generizable than in a single institutional 
cohort. There are some limitations. Firstly, although 
multi-center, the final number of patients studied may 
still be considered insufficient. Secondly, in the pursuit 
of in robust data, a cutoff of RNA quality was used, 
and a high percentage of samples were excluded from 
the analysis. Although the methodology reported could 
be refined in future studies, we maintain that we have 
a reliable prognostic biomarker for UTUC patients. 
Thirdly, although we found miRNA-31-5p down-
regulated in progressing patients, the literature supports 
the clinical value of down-regulated biomarkers in 
cancer [43]. As such, we strongly believe that our results 
are clinically applicable.
In conclusion, the current results support the 
validation of our previous finding in an independent 
cohort, confirming that miRNA-31-5p is a discriminator 
between two groups of UTUC patients having differeing 
probabilities of tumour progression. Ultimately being 
able to identify new miRNAs associated with tumour 
progression in UTUC patients will allow individualized 
medicine with tailored treatment and surveillance strategies.
PATIENTS AND METHODS
Patient population
A retrospective study in which a total of 103 
patients with UTUC who underwent nephroureterectomy 
in 4 different centres (Radboud university medical 
centre Nijmegen, Netherlands, Instituto Valenciano 
de Oncología-Spain, Hospital Universitario Reina 
Sofía of Córdoba-Spain, Hospital Clínic of Barcelona-
Spain) between 1990 and 2012 were included. The 
only exclusion criterion was lack of tissue from the 
archive blocks. Histopathological characteristics of 
the UTUC patients are shown in Table 1. None of the 
patients received neoadjuvant chemotherapy. A total of 
13 patients (12.6%) received adjuvant chemotherapy. 
Tumours were graded and classified according to 
the WHO’s [44] and the TNM’s classification of the 
International Union Against Cancer [45].
Tissue samples were obtained under institutional 
review board-approved protocol.
All patients were followed up postoperatively at 
3-month intervals for the first year, at 6-month intervals 
for the next 2 years, and annually thereafter. Physical 
examination, abdominal and pelvic CT scan, cytology and 
cystoscopy were used to follow these patients up.
Tumour was considered to be progressing when 
distant metastasis or pathological nodes developed during 
the follow-up.
Tissue specimens and RNA isolation
Upon obtainment, the tissue was fixed in 10% 
formalin within 24h and subsequently embedded in 
paraffin. A slide of each specimen was stained with 
haematoxylin-eosin to determine the presence of tumour 
cells. The pathologist revised haematoxylin-eosin slides 
and only those paraffin blocks with a minimum of 75% 
of tumour cells were selected. Total RNA was isolated 
from specimens (80-Δm) using the RecoverAll Total 
Nucleic Acid Isolation Kit (Ambion INC) according to 
the manufacturer’s protocol. Total RNA was quantified 
by spectrophotometric analysis at 260 nm (NanoDrop 
Technologies, Wilmington, DE, USA).
miRNA validation by reverse transcription 
quantitative PCR (RT-qPCR)
RT-qPCR reactions were performed according to the 
manufacturers’ instructions (Exiqon, Vedbaek, Denmark). 
Briefly, cDNA was synthesized using a poly(T) primer 
and was amplified with locked nucleic acid (LNA) 
primers and SYBR Green master mix. Specific LNA PCR 
primer sets used were miRNA-31-5p and miRNA-149-
5p. miRNA-218-5p was used as an endogenous control 
[17] and its expression was assessed in all samples. Those 
samples with a Ct value ≥ 30 for endogenous control were 
considered of low RNA quality and were excluded from 
the analysis (n=68). In the remaining samples, expression 
of miRNA-149-5p and miRNA-31-5p was analyzed. 
PCR reactions were carried out using specific miRNA 
protocol conditions provided by the manufacturers in an 
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ABI7900HT instrument. At the end of the PCR cycles, 
melting curve analyses were performed.
Data analysis
RT-qPCR data was analyzed using SDS 2.4 software 
(Applied Biosystems). An automatic baseline and a 
manual threshold of 2.0 were used for all miRNAs to 
record Cq values. Each experiment included a negative 
non-template control and an inter-experiment control. 
miRNA-218-5p was selected by using GeNorm as 
reference miRNA [46,47]. Relative expression levels of 
target miRNAs within a sample were expressed as ΔCt 
(CtmiR218 – Ct target miRNA).
Statistical analysis
The probabilities of progression-free survival and 
cancer-specific survival were calculated using Kaplan-
Meier curves. Statistical differences were identified 
by the log-rank test. Hazard ratios and their confidence 
interval were calculated. Spearman Test was used for 
correlations. In the multivariate analysis forward stepwise 
Cox regression was performed. Statistical significance 
was established at a p-value of 0.05, and accordingly 95% 
confidence intervals (CI) around hazard ratios (HR) are 
presented. SPSS 23.0 software was used for statistical 
analysis. Thereafter, Kaplan-Meier curves were generated. 
For this analysis, miRNA expression was dichotomized 
using the median value (-2.27) of miRNA-31-5p as a cut-
off value.
Pathway enrichment analysis
The DIANA-mirPath tool [48], using TargetScan as 
the target prediction algorithm, was used to identify the 
targets of miR-31-5p, and subsequent target enrichment 
analysis was performed in order to discover possible 
canonical altered pathways.
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